(AMBS) Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy. (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").
ESS, previously known as PermaDerm® is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015.
For further information, please visit www.Amarantus.com, or connect with the company in Facebook, Twitter, LinkedIn & Google+
|PRESS RELEASES & NEWS ARTICLES |
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 29, 2015
Amarantus BioScience Initiation of coverage Building up therapeutics assets
July 27, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee - Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
July 27, 2015
SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34
JULY 24, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 20, 2015
Amarantus Closes Cutanogen Acquisition
By Jason Napodano, CFA - Wednesday, July 15, 2015
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns - Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS) - July 15, 2015
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS - Company Progressing Toward a National Stock Exchange Listing. - July 13, 2015
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease - Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson's Disease - June 30, 2015
Amarantus Sets Sights On NASDAQ
Jason Napodano, CFA - May 29, 2015
Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch - Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -
May 20, 2015
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease - Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
May 13, 2015
Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015
Gerald E. Commissiong on LymPro
Published on Jul 24, 2015
Predicting Alzheimer's before it starts
Published on Apr. 8, 2015
Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014
Oct. 19, 2014
Amarantus BioScience Holdings, Inc.
655 Montgomery Street
San Francisco, CA 94111
c/o ICS Corporate Services SA
29 quai du Mont Blanc
email@example.com Phone: (415) 688-4484 Fax: (408) 852-4427 Gerald's email address
Gerald@amarantus.com IR Calendar
Jenene Thomas Communications
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF. This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline. Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise. Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
"We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.